MicroRNA-29b Plays a Vital Role in Podocyte Injury and Glomerular Diseases through Inducing Mitochondrial Dysfunction

Area of Science:

• Nephrology
• Molecular Biology
• Biochemistry

Background:

• Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease (ESRD).
• Podocyte injury and mitochondrial dysfunction are key drivers of DKD progression.
• MicroRNAs (miRNAs) are implicated in the pathogenesis of kidney diseases.

Purpose of the Study:

• To investigate the role of miR-29b in DKD pathogenesis.
• To identify miR-29b as a potential biomarker for podocyte injury and DKD.
• To elucidate the molecular mechanism of miR-29b in DKD.

Main Methods:

• Urine analysis in 126 DKD patients (stages I and II).
• In vitro studies using cell cultures to assess miR-29b's effect on podocytes and PGC-1α.
• In vivo studies using ADR nephropathy and db/db mouse models, including podocyte-specific miR-29b knockout mice.

Main Results:

• miR-29b levels were elevated in DKD patients' urine and correlated negatively with kidney function and podocyte homeostasis.
• miR-29b directly targeted PGC-1α, a regulator of mitochondrial biogenesis.
• In vitro and in vivo, miR-29b promoted podocyte injury and DKD progression, while its inhibition or knockout mitigated these effects.
• miR-29b inhibition preserved kidney function and reduced podocyte injury in mouse models.

Conclusions:

• miR-29b exacerbates DKD by targeting PGC-1α, leading to mitochondrial dysfunction and podocyte injury.
• miR-29b is a promising urinary biomarker for early detection of podocyte injury and DKD.
• Targeting miR-29b may offer a therapeutic strategy for DKD.